Cboe Global Markets CBOE

Reference table

1. What it is

Cboe Global Markets (BATS: CBOE) is a global exchange operator founded in Chicago in 1973, best known as the home of listed options — and specifically the proprietary, exclusively-licensed SPX (S&P 500) and VIX index-options franchise, which is the profit engine and the source of the moat. The company reports five segments: Options (the crown jewel), North American Equities (cash equities/ETPs in the US and Canada), Europe and Asia Pacific, Futures, and Global FX. Alongside trading it runs a fast-growing recurring-revenue data business, Cboe Data Vantage (market data, analytics, and access/capacity fees). Fiscal year ends December 31; CEO is Craig Donohue (in seat ~1 year, driving a strategic realignment).

A crucial reporting note (read before the financials). Exchanges are reported two ways. FMP's income statement shows gross revenue (FY25 $4,714M), which includes large pass-through items — liquidity payments, routing/clearing, Section 31 fees — that CBOE collects and remits. What management and analysts actually track is net revenue (revenue less cost of revenue): Q1'26 net revenue was $728.9M, up 29% per the earnings release, and the full-year analyst estimates (~$2.4–3.3B) are on this net basis. Throughout this note, growth and margin commentary use the net-revenue frame; where a number is gross, it is labeled.

Revenue mix — net revenue by segment (Q1'26, from the earnings release):

• Options $467.6M (+33%) — the franchise, ~64% of net revenue
• North American Equities $111.2M (+18%)
• Europe and Asia Pacific $84.9M (+32%)
• Futures $35.8M (+9%)
• Global FX $29.4M (+38%)

By revenue caption (FY25 gross, from filings): Transaction & clearing fees $3,597.6M · Access & capacity fees $408.7M · Market data fees $326.6M · Regulatory fees $285.4M · Other $95.9M. The Access/capacity + Market data lines (~$735M gross) are the sticky, recurring Data Vantage revenue that management is investing behind. (FMP's geographic segmentation is incomplete for FY25 — it lists only North American Equities $1,672M and Europe/APAC $379M — so the segment table above from the earnings release is the reliable cut.)

2. The expert thesis — the one traceable voice (and it's thin)

Honest breadth statement: the Synthos KB has exactly one claim on CBOE. This is not a conviction-panel name like our flagship healthcare ideas; the verdict here is fundamentals- and quant-driven, with the single expert voice used only as corroboration.

• The one voice (bullish, corroborating the setup). Compound & Friends (compound_and_friends-QzbZSLClQag:90df227007, bullish, conviction 55, skill 1.0): the "exchange-stock crash on fears that perps displace listed futures is overdone; the selloff is an overreaction." That claim maps precisely onto what the price action shows — CBOE down 32% from its high while fundamentals accelerated — which is the crux of the Buy — Tactical case.

That is the entire expert record. There is no bearish KB voice on file and no high-breadth panel, so we do not manufacture conviction we don't have: the score and the verdict below are built from the financials, the valuation, and the disruption debate on their own merits.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores summarize them.

Synthos fair value = the base case, ~$287 (+15%), with the full $192–$384 span as the honest range. Our base sits just below the Street's $302 consensus (we apply a disruption haircut to the multiple) while our bull roughly matches the Street's $335 high. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). CBOE is a high-quality compounder with a genuine near-term acceleration, but structurally capped:

• Forward growth: net-revenue CAGR is modest (~6–8% on the FY26E→FY30E estimate path, $2.80B → $3.33B), but EPS CAGR is ~12% (FY25 $10.42 → FY30E $18.55) as buybacks, mix, and the realignment lift margins.
• Acceleration (the 2nd derivative) is positive right now: management raised 2026 organic net-revenue growth guidance to low-double-digit-to-mid-teens from mid-single-digit, and Q1'26 net revenue +29% / EPS +54% are records. That is a real, dated inflection — the reason a Buy is on the table at all. But it is a cyclical/volatility-driven acceleration, not a new secular S-curve; the estimates fade it back toward high-single-digit by FY28–30.
• Room to run: at $26B the cap is not the binding constraint the way a $1T name is, but the TAM is modest — global listed-derivatives and market-data economics grow steadily, not exponentially, and CBOE already owns the highest-value slice.
• The disruption wildcard: perpetual futures and tokenization are the swing factor. If they expand the derivatives market and CBOE captures the tokenization/clearing build-out management is investing in, that's optionality. If they migrate volume off-exchange, it's the bear case. Today it reads as threat-heavy.

Exponential Potential: Moderate (4/10). Own CBOE for a ~25% ROE, a protected franchise, and a credible near-term earnings acceleration at a fair price — not for a fast multibagger.

5. Financials (real numbers — FMP annual/quarterly + the earnings release)

• Net revenue (the number that matters): Q1'26 $728.9M, +29% YoY (earnings release). On a gross basis FMP shows FY25 revenue $4,714M (+15%) and Q1'26 $1,272.8M, but that includes pass-throughs — use the net frame.
• Earnings: FY25 diluted EPS $10.42 (GAAP), up from $7.21 FY24. Q1'26 diluted EPS $3.66, +54% (adjusted $3.70, +48%) — a record quarter. Q1'26 net income $385.7M.
• Margins (net-revenue basis, from the release): Q1'26 operating margin 69.4% (adjusted 72.4%), net-income margin 52.7%, EBITDA margin 73.9% — and expanding ~6pp YoY. Elite for any business.
• Returns on capital: ROE 24.6% TTM, ROA 11.2%, ROIC 10.6%. High-quality earner.
• Cash flow: FY25 operating cash flow $1,224M, capex only −$71M (asset-light), free cash flow $1,153M — a ~93% FCF/OCF conversion. FCF yield ~4.3%.
• Balance sheet — a fortress: cash & ST investments $2,253M, total debt $1,685M → net cash of ~$0.53B (net-debt/EBITDA −0.30×). Current ratio 4.1×, interest coverage ~31×. This is a genuinely low-risk balance sheet.

6. Valuation — priced in or room?

CBOE is not expensive on its own history or on forward earnings — the debate is entirely about whether the earnings are durable:

• Trailing: 21.2× EPS, 13.4× EV/EBITDA, 5.4× sales, ~4.9× book. FMP's letter rating is A− (overall score 4/5; ROE and ROA score 5/5).
• Forward (on consensus EPS): 18.4× FY26E ($13.53) → 17.3× FY27E ($14.36) → 13.4× FY30E ($18.55). The multiple compresses steadily even at a flat price if estimates hold — CBOE has historically traded closer to 22–25×, so today's ~17–18× forward embeds a visible disruption discount.
• The setup: a ~25%-ROE, net-cash, wide-moat monopolist growing EPS mid-teens near-term, at ~18× forward and −32% off its high. That is cheap for the quality — if the perps/tokenization fear is overdone (exactly the Compound & Friends claim). If it isn't, the discount is earned.
• Street targets (context): consensus $302, high $335, low $263. Our $287 base sits modestly below consensus because we haircut the multiple for the overhang; our bull ~$384 is above the Street high.

Read: a quality-franchise-at-a-fair-price buy, not a deep-value bargain and not an expensive momentum name.

7. Technicals (computed from EOD price history)

• Trend: down. $249 sits below the 50-DMA ($306) and 200-DMA ($275), with the 50 now below the 200 — a bearish posture. MACD −19.2 (negative).
• Location: −32% off the 52-week high ($366.70), only +7.6% off the 52-week low ($231.35) — this is a broken chart, near the lower end of its range, with a max drawdown of −32% from peak.
• Momentum: RSI(14) 26 — oversold (<30). Statistically stretched to the downside, which can precede a bounce but also confirms real distribution.
• Relative strength (the tell against the thesis): CBOE +7.3% 12-mo vs SPY +20.6% and QQQ +30.3%; −11% over 3 months while SPY rose +14%. Persistent, broad underperformance — the market is voting that something is wrong, which is the risk the bull case has to overcome.
• Read: technicals contradict the fundamentals — accelerating earnings but a falling, oversold stock. That divergence is precisely the "overreaction" setup, but it is not yet confirmed by price. A tactical buyer should scale in and want to see the downtrend base and the 50-DMA flatten before adding.

8. Moat & competitive position

CBOE's moat is one of the widest in financial services and rests on three pillars: (1) proprietary, exclusively-licensed products — SPX and VIX index options cannot be listed elsewhere, so CBOE captures the economics of the single most important equity-index-volatility complex; (2) network liquidity — options liquidity begets liquidity, entrenching incumbents; and (3) a growing recurring data/access franchise (Data Vantage) that is stickier and less volume-cyclical than transaction fees. Returns on capital (~25% ROE) and ~70% operating margins are the financial signature of that moat.

The threat — and the reason the stock is down — is structural: perpetual futures (24/7, crypto-native contracts) and tokenization could route derivatives and equities volume to always-on, off-exchange venues, eroding the protected franchise over time. Management is not passive — it is explicitly investing in tokenization initiatives, event markets, and expanded clearing (see §9) — but this is the open question the multiple is pricing.

Peer set (market cap, from FMP). FMP's "peers" list is a loose financials basket, not a clean exchange comp: Tradeweb (TW) $21.9B and Futu (FUTU) $13.3B are the closest market-structure names; the rest — Cincinnati Financial (CINF) $29.7B, First Citizens (FCNCA) $24.1B, Huntington (HBAN) $36.2B, LPL Financial (LPLA) $23.6B, Markel (MKL) $24.8B, Shinhan (SHG) $31.6B, U.S. Bancorp (USB) $95.8B — are banks/insurers. CBOE's truest comps (ICE, CME, Nasdaq, LSEG) are not in this list; on the standard exchange-peer frame CBOE typically screens with the highest margins and a mid-pack multiple.

9. Management, capital allocation & guidance

• Capital allocation: asset-light and shareholder-friendly — FY25 FCF $1,153M funded $284M of dividends (payout ~24%, yield ~1.16%) and $96.5M of buybacks, while the balance sheet ran net cash. Ample capacity to lean into buybacks at a depressed price or to fund the growth investments below.
• Insider activity: the sampled window is dominated by routine director equity awards (mostly $0-price grants dated 2026-05-14) plus small tax-withholding dispositions; one discretionary director sale (Froetscher, 1,223 shares at $358 on 2026-05-18 — near the highs, before the drawdown). No alarming cluster of discretionary insider selling at current prices.
• Management's own guidance — the earnings-call track (half-weighted; they talk their book). The Q1'26 earnings release (SEC 8-K Item 2.02, filed 2026-05-01) is a real release with concrete forward guidance, so we summarize it as management's own, self-interested words:

- Raised 2026 total organic net-revenue growth target to "low double-digit to mid-teens" from "mid single-digit."

- Raised Data Vantage organic net-revenue growth target to "low double-digit" from "mid-to-high single-digit."

- Lowered 2026 adjusted operating-expense guidance to $838–$853M from $864–$879M (via a strategic realignment cutting workforce ~20%, and selling Cboe Canada and Cboe Australia).

- CEO Donohue framed a portfolio "realignment" to concentrate on core earnings drivers and invest in event markets, tokenization, and expanded US/Europe clearing.

- Half-weight caveat: this is management's own framing after a record quarter — genuinely positive, but it is the bull's evidence and should be read alongside the technicals in §7, which disagree.

10. Catalysts & what to watch

• Next earnings: 2026-07-31 (Q2'26; Street EPS $3.30). The key lines: Options net revenue and total ADV (is the SPX/VIX volume acceleration holding), and Data Vantage growth vs the raised low-double-digit target.
• Guidance re-confirmation: whether management holds or nudges the raised full-year organic net-revenue target.
• Realignment execution: the ~20% workforce reduction and the Canada/Australia divestitures landing in the opex line ($838–$853M target) — margin proof.
• The disruption watch: any hard data on perpetual-futures / tokenized-venue volume migration (for or against the thesis) is the single most important external signal.
• Buyback pace: whether management accelerates repurchases into the drawdown (a tell on their own conviction).

Thesis tripwires (what would change the call): two consecutive quarters of Options volume deceleration; concrete evidence of durable volume migration to perps/tokenized venues; net-revenue growth slipping below the raised guidance range; or the multiple staying depressed while estimates get cut (a value trap confirming).

11. Key risks

• Secular disruption (the structural one, and the reason for the discount): perpetual futures and tokenization could route derivatives/equities volume off-exchange and erode the protected SPX/VIX franchise. The lone KB voice argues the fear is overdone (compound_and_friends-QzbZSLClQag:90df227007) — but "overdone" is a judgment, not a fact, and the price action currently disagrees.
• Volume cyclicality: transaction fees are the majority of revenue and are tied to trading activity and volatility; a low-volatility, low-volume regime compresses the growth the bull case needs.
• Technical downtrend: −32% drawdown, below both moving averages, 12-month underperformance vs SPY and QQQ — the market is pricing a problem the bull has to disprove.
• Regulatory / product-exclusivity risk: the moat depends on index-licensing and regulatory structure; changes to either would hit the crown jewel.
• Thin expert coverage: only 1 KB claim, so there is no diversified expert cross-check — conviction is deliberately Low and sizing is Tactical.

12. Verdict, position sizing & monitoring

Buy — Tactical. CBOE is a wide-moat, net-cash, ~25%-ROE derivatives monopolist that just posted a record quarter (net revenue +29%, EPS +54%) and raised guidance, trading at ~18× forward and −32% off its high because the market fears perpetual futures and tokenization will erode the franchise. If that fear is overdone — as the one traceable KB voice argues and the accelerating fundamentals suggest — today's price is an attractive entry into quality. But the fear is not baseless, the chart is in a confirmed downtrend, and expert breadth is a single voice, so this is a Tactical, satellite-sized recovery idea, not a Core anchor.

• Sizing: tactical / value-recovery, ~2–3% satellite weight. Scale in against the downtrend rather than a single lump; the oversold RSI (26) argues for patience on a base rather than chasing.
• Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next 2026-07-31). This verdict is logged as a tracked Synthos call as of 2026-07-03 at $248.99.
• Single biggest risk: durable volume migration to perpetual-futures and tokenized venues — the one development that would turn a cheap-looking price into a value trap.

Provenance & disclosures

• Traceability: 1 KB claim, breadth 1, top skill 1.0 (Compound & Friends), reconciled to a real claim_id (cited inline). This is explicitly a fundamentals-and-quant verdict; conviction is rated Low by design because expert breadth is a single voice. Fabricated conviction is structurally impossible (claim-ID reconciliation).
• Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-03 · management guidance from the SEC 8-K earnings release filed 2026-05-01 · expert claim through 2026-07-03. Forward figures are analyst consensus (FMP) or management guidance, each labeled as an estimate.
• Reporting note: all growth/margin commentary uses net revenue (revenue less cost of revenue), the exchange-industry standard; FMP's gross revenue includes pass-through liquidity/routing/Section-31 items and is labeled where used.
• Management caveat: the Q1'26 guidance is management's own book, half-weighted by design, and disagrees with the technical picture.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").